enrollment

Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research

Source Node:
Time Stamp: August 29, 2023 8:20 AM - Modified On: August 29, 2023 - Published By:
Source Cluster:
Republished By Plato

Gain Therapeutics, Inc. (Nasdaq: GANX), a pioneering biotechnology company specializing in innovative allosteric small molecule therapies, has made significant strides in the fight against Parkinson's disease (PD). The Company's lead drug candidate, GT-02287, has demonstrated extraordinary potential in mitigating the effects of Parkinson's disease across two distinct preclinical models of the ailment. These findings suggest that GT-02287 has the capacity to alleviate Parkinson's disease pathology and enhance motor function. A notable highlight is the substantial reduction of plasma Neurofilament Light Chain (NfL) levels, an emerging biomarker for neurodegeneration. This advancement

SCCG Announces Strategic Partnership with AWARE, A Global Leader in KYC Software Solutions

Source Node:
Time Stamp: August 7, 2023 12:39 PM - Modified On: August 7, 2023 - Published By:
Source Cluster:
Republished By Plato

SCCG Management announced a strategic partnership with AWARE, a world leader in biometric verification software solutions. This partnership aims to establish AWARE’s superior biometric software solutions in the global gambling industry, with SCCG leading the charge to distribute these innovative solutions to major operators worldwide. AWARE, a pioneering company listed on the NASDAQ under the ticker symbol "AWRE," has dramatically transformed the landscape of security and authentication with its comprehensive portfolio of innovative biometric solutions. These ground-breaking solutions enable secure biometric enrollment, authentication, and identity verification, facilitating seamless transactions, and

Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease.

Source Node:
Time Stamp: June 7, 2023 12:22 PM - Modified On: June 7, 2023 - Published By:
Source Cluster:
Republished By Plato

Highlights Coya reports new data illustrating that administration of COYA 301 (low dose Interleukin-2 (IL-2)) in an open- label study in 8 patients with mild to moderate AD (COYA 301 Trial) resulted in a statistically significant reduction in the expression of three well characterized proinflammatory cytokines -- Tumor Necrosis Factor alpha (TNF-α), Interleukin 6 (IL-6), and Interleukin 1- Beta (IL-1β) -- which correlated with lack of cognitive decline of the patients over the course of the study. TNF-α is one of the main inflammatory cytokines involved in initiating and propagating